94 completed, 33 terminated, 9 active not recruiting, 5 withdrawn. 59 Phase 2, 44 Phase 1, 43 Not applicable, 3 Early Phase 1, 3 Phase 3.
Follow Stage IIIB Breast Cancer: new trials by email Literature Review of Stage IIIB Breast Cancer trials Research Report on Stage IIIB Breast Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Exercise Intervention in Targeting Adiposity and Inflammation With Movement to Improve Prognosis in Breast Cancer Exercise Intervention, Informational Intervention, Laboratory Biomarker Analysis - Cancer Survivor, Central Obesity | Not applicable | Withdrawn | University of Southern California | 2019-07-29 | 2019-10-24 | |
| Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer Anti-OX40 Antibody PF-04518600, Avelumab, Binimetinib - Stage III Breast Cancer, Stage IIIA Breast Cancer | Phase 2 | Active not recruiting | Laura Huppert, MD, BA | 145 | 2019-07-08 | 2026-04-17 |
| Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer Atezolizumab, Cobimetinib, Idasanutlin - Stage III Breast Cancer, Stage IIIA Breast Cancer | Phase 1 / Phase 2 | Terminated | Vanderbilt-Ingram Cancer Center | 12 | 2018-07-10 | 2021-08-11 |
| Acceptance and Commitment Therapy in Improving Well-Being in Patients With Stage III-IV Cancer and Their Partners Cognitive Behavior Therapy, Quality-of-Life Assessment, Questionnaire Administration - Malignant Female Reproductive System Neoplasm, Malignant Hepatobiliary Neoplasm | Not applicable | Completed | Rutgers, The State University of New Jersey | 14 | 2017-12-06 | 2021-04-08 |
| 4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer Utomilumab, Trastuzumab, Ado-Trastuzumab Emtansine - HER2 Positive Breast Carcinoma, Recurrent Breast Carcinoma | Phase 1 | Completed | George W. Sledge Jr. | 18 | 2017-10-30 | 2022-10-19 |
| Aerobic and Strength Training Exercise in Improving Fitness and Arm Health During and After Radiation Therapy in Patients With Stage II-III Breast Cancer Best Practice, Exercise Intervention, Quality-of-Life Assessment - Stage II Breast Cancer, Stage IIA Breast Cancer | Not applicable | Completed | Ohio State University Comprehensive Cancer Center | 4 | 2017-08-30 | 2023-12-14 |
| Exercise in Targeting Metabolic Dysregulation in Stage I-III Breast or Prostate Cancer Survivors Exercise Intervention, Laboratory Biomarker Analysis, Polar heart rate monitor - Cancer Survivor, No Evidence of Disease | Not applicable | Terminated | University of Southern California | 23 | 2017-08-17 | 2025-09-29 |
| Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer Biopsy of Breast, Copanlisib, Laboratory Biomarker Analysis - Estrogen Receptor Positive, HER2/Neu Negative | Phase 1 | Terminated | Jonsson Comprehensive Cancer Center | 10 | 2017-08-02 | 2022-09-26 |
| Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer Alisertib, Fulvestrant, Laboratory Biomarker Analysis - Estrogen Receptor Status, HER2/Neu Negative | Phase 2 | Completed | Mayo Clinic | 96 | 2017-07-06 | 2026-09-24 |
| Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery Capecitabine, Laboratory Biomarker Analysis, Pembrolizumab - Estrogen Receptor Negative, HER2/Neu Negative | Phase 2 | Unknown | Northwestern University | 30 | 2017-05-25 | 2020-07-13 |
| Ultrasound in Detecting Taxane-Induced Neuropathy in Patients With Breast Cancer Biopsy, Questionnaire Administration, Ultrasound Tomography - Peripheral Neuropathy, Stage 0 Breast Cancer | Not applicable | Completed | Wake Forest University Health Sciences | 20 | 2017-05-11 | 2024-04-08 |
| Mindfulness Meditation or Survivorship Education in Improving Behavioral Symptoms in Younger Stage 0-III Breast Cancer Survivors (Pathways to Wellness) Educational Intervention, Laboratory Biomarker Analysis, Meditation Therapy - Cancer Survivor, Early-Stage Breast Carcinoma | Not applicable | Unknown | Jonsson Comprehensive Cancer Center | 96 | 2017-02-20 | 2022-07-21 |
| Endocrine Therapy Fulvestrant & Palbociclib or Aromatase Inhibitor Therapy in Treating Older Patients With Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery Fulvestrant, Laboratory Biomarker Analysis, Palbociclib - Estrogen Receptor and/or Progesterone Receptor Positive, HER2/Neu Negative | Phase 2 | Completed | Ohio State University Comprehensive Cancer Center | 14 | 2017-02-16 | 2025-12-19 |
| Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca Doxorubicin, Cyclophosphamide, Paclitaxel - Breast Adenocarcinoma, Estrogen Receptor- Negative Breast Cancer | Phase 2 | Active not recruiting | Virginia Commonwealth University | 46 | 2017-01-24 | 2026-07-01 |
| Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors Carboplatin, Cisplatin, Palbociclib - Solid Neoplasm, Stage III Pancreatic Cancer | Phase 1 | Completed | Emory University | 71 | 2016-10-24 | 2023-10-10 |
| S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER) Preventive Intervention, Quality-of-Life Assessment, Questionnaire Administration - Febrile Neutropenia, Stage 0 Breast Cancer | Not applicable | Completed | SWOG Cancer Research Network | 3665 | 2016-10-07 | 2022-10-20 |
| Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission Laboratory Biomarker Analysis, pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine, Sargramostim - HER2/Neu Negative, No Evidence of Disease | Phase 1 | Completed | University of Washington | 32 | 2016-09-02 | 2024-09-19 |
| MRI and Cardio-Pulmonary Exercise Testing in Evaluating Exercise Intolerance in Patients With Stage I-III Breast Cancer After Chemotherapy Treatment Cardiopulmonary Exercise Testing, Magnetic Resonance Imaging - Healthy Subject, Stage IA Breast Cancer | Completed | Wake Forest University Health Sciences | 33 | 2016-08-25 | 2019-04-26 | |
| Functional Magnetic Resonance Imaging in Assessing Affect Reactivity and Regulation in Patients With Stage 0-III Breast Cancer Biospecimen Collection, Functional Magnetic Resonance Imaging, Questionnaire Administration - Healthy Subject, Stage 0 Breast Cancer | Completed | Stanford University | 178 | 2016-08-01 | 2022-07-27 | |
| Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer Copper Cu 64-DOTA-Trastuzumab, Laboratory Biomarker Analysis, Pertuzumab - HER2 Positive Breast Carcinoma, Stage IIIA Breast Cancer | Phase 2 | Active not recruiting | City of Hope Medical Center | 18 | 2016-07-15 | 2025-11-14 |
Showing 20 of 144. Sign in to see all of them.
Breast Neoplasms (144) · Breast Neoplasms, Male (39) · Triple Negative Breast Neoplasms (17) · Breast Carcinoma In Situ (14) · Carcinoma, Ovarian Epithelial (11) · Inflammatory Breast Neoplasms (10) · Carcinoma, Intraductal, Noninfiltrating (9) · Carcinoma, Renal Cell (8) · Colonic Neoplasms (7) · Prostatic Neoplasms (7) · Testicular Neoplasms (7) · Burkitt Lymphoma (6) · Carcinoma, Non-Small-Cell Lung (6) · Hodgkin Disease (6) · Leukemia, Lymphocytic, Chronic, B-Cell (6)
Breast Diseases (144) · Neoplasms by Site (144) · Skin Diseases (144) · Skin and Connective Tissue Diseases (144) · Neoplasms (143) · Neoplasms by Histologic Type (39) · Carcinoma (36) · Neoplasms, Glandular and Epithelial (36) · Urogenital Diseases (22) · Urogenital Neoplasms (22) · Adenocarcinoma (20) · Endocrine Gland Neoplasms (20) · Endocrine System Diseases (20) · Female Urogenital Diseases (20) · Female Urogenital Diseases and Pregnancy Complications (20)
Taxes (21) · Paclitaxel (19) · Cyclophosphamide (14) · Doxorubicin (14) · Carboplatin (12) · Trastuzumab (12) · Early Intervention, Educational (10) · Methods (9) · Magnetic Resonance Spectroscopy (8) · Anastrozole (7) · Tamoxifen (7) · 2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide (6) · Albumin-Bound Paclitaxel (6) · Fulvestrant (6) · Letrozole (6)
National Cancer Institute (NCI) (35) · University of Washington (13) · University of Southern California (11) · City of Hope Medical Center (8) · Wake Forest University Health Sciences (8) · Ohio State University Comprehensive Cancer Center (7) · Mayo Clinic (5) · Fred Hutchinson Cancer Center (4) · Northwestern University (4) · Rutgers, The State University of New Jersey (4) · Case Comprehensive Cancer Center (3) · Emory University (3) · Jonsson Comprehensive Cancer Center (3) · Stanford University (3) · ECOG-ACRIN Cancer Research Group (2)
United States (139) · Canada (4) · Puerto Rico (2) · South Africa (1)
Joseph Sparano (3) · Christina Dieli-Conwright, Ph.D. (2) · Dawn Hershman (2) · Elaina Gartner (2) · Hannah Linden (2) · Jennifer Specht (2) · Joanne Mortimer (2) · Lupe Salazar (2) · Mary Disis (2) · Rita Nanda (2) · Vered Stearns (2) · William Hundley (2) · Agustin Garcia (1) · Agustin Garcia, MD (1) · Amulya C Yellala, MD (1)
PMID 18650156, PMID 18974373, PMID 19153124, PMID 22200869, PMID 22827973, PMID 24068539, PMID 24154719, PMID 24210070, PMID 24708832, PMID 25965900, PMID 26006067, PMID 26059540, PMID 26062933, PMID 26276750, PMID 26359256, PMID 26611425, PMID 28045625, PMID 28764748, PMID 28817727, PMID 29233615, PMID 29356607, PMID 29440043, PMID 29961039, PMID 30340503, PMID 30535101, PMID 30549145, PMID 30850872, PMID 30920602, PMID 31236810, PMID 31269914, PMID 31277699, PMID 31309977, PMID 32060053, PMID 32808383, PMID 33292676, PMID 33929533, PMID 34018031, PMID 34092112, PMID 34406839, PMID 34413391, PMID 35365139, PMID 35795051, PMID 36130057, PMID 36228177, PMID 36279134, PMID 36326756, PMID 36892847, PMID 37083300, PMID 37770704, PMID 37788414
N01CM62204 (6), P30CA015704 (6), P30CA012197 (5), P30CA015083 (5), P30CA013330 (4), P30CA014089 (4), P30CA014520 (4), P30CA016672 (4), P30CA072720 (3), U01CA062487 (3), U01CA062491 (3), U01CA076576 (3), N01CM62202 (2), N01CM62205 (2), N01CN35159 (2)